| Literature DB >> 28710006 |
Katrin Fuchs1, Rafael Duran2, Alban Denys3, Pierre E Bize4, Gerrit Borchard5, Olivier Jordan6.
Abstract
Embolic microspheres or beads used in transarterial chemoembolization are an established treatment method for hepatocellular carcinoma patients. The occlusion of the tumor-feeding vessels by intra-arterial injection of the beads results in tumor necrosis and shrinkage. In this short review, we describe the utility of using these beads as devices for local drug delivery. We review the latest advances in the development of non-biodegradable and biodegradable drug-eluting beads for transarterial chemoembolization. Their capability to load different drugs, such as chemotherapeutics and anti-angiogenic compounds with different physicochemical properties, like charge and hydrophilicity/hydrophobicity, are discussed. We specifically address controlled and sustained drug release from the microspheres, and the resulting in vivo pharmacokinetics in the plasma vs. drug distribution in the targeted tissue.Entities:
Keywords: Antiangiogenic; Bevacizumab (PubChem CID: 24801580); Biodegradable; Cisplatin (PubChem CID 441203); Controlled release; Degradable; Doxorubicin Hydrochloride (PubChem CID: 443939); Drug-eluting beads; Hepatocellular carcinoma; Ibuprofen (PubChem CID: 3672); Irinotecan (PubChem CID: 60838); Local delivery; Microspheres; N-Desethyl Sunitinib (PubChem CID: 10292573); Pharmacokinetics; Rapamycin (PubChem CID: 5284616); Sorafenib (PubChem CID: 216239); Sunitinib (PubChem CID: 5329102); Transarterial chemoembolization; Vandetanib (PubChem CID: 3081361)
Mesh:
Substances:
Year: 2017 PMID: 28710006 DOI: 10.1016/j.jconrel.2017.07.016
Source DB: PubMed Journal: J Control Release ISSN: 0168-3659 Impact factor: 9.776